Suppr超能文献

血管紧张素转换酶抑制剂诱导血管性水肿的药物治疗:系统评价。

Pharmacotherapy for Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema: A Systematic Review.

机构信息

1 Department of Otolaryngology-Head and Neck Surgery, School of Medicine, Tulane University, New Orleans, Louisiana, USA.

2 Department of Otorhinolaryngology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA.

出版信息

Otolaryngol Head Neck Surg. 2018 Feb;158(2):232-239. doi: 10.1177/0194599817737974. Epub 2017 Nov 7.

Abstract

Objective Angioedema is a potentially life-threatening complication of angiotensin-converting enzyme inhibitor (ACEI) use, occurring in up to 0.5% of users. Although the pathophysiology of ACEI-induced angioedema is attributable to elevated serum bradykinin, standard management typically includes corticosteroids and antihistamines. We sought to summarize the evidence supporting pharmacotherapy for ACEI-induced angioedema. Data Sources PubMed, MEDLINE, and Embase portals. Methods A systematic literature review was conducted according to the PRISMA guidelines. Databases were queried by 3 independent reviewers for English-language studies published between 1980 and 2017. The initial search screened for all occurrences of "angioedema" and then was further refined to include studies of ACEI-related cases and exclude hereditary angioedema. Results Five articles representing 218 cases were identified, including 3 randomized controlled trials and 2 prospective case series with historical controls. One of 2 studies of icatibant (bradykinin B2 receptor antagonist) found more rapid symptom improvement than that with a control group of corticosteroids and antihistamines. Two studies of ecallantide (plasma kallikrein inhibitor) and 1 study of C1 inhibitor replacement found no significant benefit over control. No studies were identified that compared the efficacy of corticosteroids with antihistamines, of one dose with another, of fresh frozen plasma, or of combination therapy. Conclusion The efficacy of treatment of ACEI-induced angioedema with bradykinin antagonists, kallikrein inhibitor, and C1 inhibitor warrants further study. Although consistent benefit of these medications has not been demonstrated, their use has not caused harm. One study examining off-label use of icatibant has demonstrated efficacy over control. In addition, further study is needed to establish the efficacy and mechanism of action of standard pharmacotherapy such as corticosteroids and antihistamines in treatment of this condition.

摘要

目的血管性水肿是血管紧张素转换酶抑制剂(ACEI)使用的一种潜在危及生命的并发症,在多达 0.5%的使用者中发生。尽管 ACEI 引起的血管性水肿的病理生理学归因于血清缓激肽升高,但标准治疗通常包括皮质类固醇和抗组胺药。我们试图总结支持 ACEI 引起的血管性水肿的药物治疗的证据。

数据来源 PubMed、MEDLINE 和 Embase 门户。

方法根据 PRISMA 指南进行系统的文献回顾。由 3 名独立评审员在 1980 年至 2017 年期间以英语发表的研究中查询数据库。初始搜索筛选出所有“血管性水肿”的发生情况,然后进一步细化为包括 ACEI 相关病例的研究,并排除遗传性血管性水肿。

结果确定了 5 篇文章,代表 218 例,包括 3 项随机对照试验和 2 项具有历史对照的前瞻性病例系列。2 项依卡替班特(缓激肽 B2 受体拮抗剂)研究中的 1 项发现症状改善比皮质类固醇和抗组胺药对照组更快。2 项艾卡替班特(血浆激肽释放酶抑制剂)研究和 1 项 C1 抑制剂替代研究发现与对照组相比没有显著获益。没有研究比较皮质类固醇与抗组胺药、一种剂量与另一种剂量、新鲜冷冻血浆或联合治疗的疗效。

结论使用缓激肽拮抗剂、激肽释放酶抑制剂和 C1 抑制剂治疗 ACEI 引起的血管性水肿的疗效需要进一步研究。尽管这些药物的一致益处尚未得到证实,但它们的使用没有造成危害。一项研究检查了依卡替班特的标签外使用,证明了其疗效优于对照组。此外,还需要进一步研究以确定皮质类固醇和抗组胺药等标准药物治疗在治疗这种疾病中的疗效和作用机制。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验